Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry.
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DYDA2
- 07 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 07 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 07 Feb 2015 New trial record